Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. - Wikidata - wikimedia - TriplyDB

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

http://www.wikidata.org/entity/Q34165147

about

The clinical management of Type 2 Gaucher disease Efferocytosis is impaired in Gaucher macrophages.A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response.Induced pluripotent stem cell models of lysosomal storage disorders.A novel role for 12/15-lipoxygenase in regulating autophagy Zinc-α2-Glycoprotein Modulates AKT-Dependent Insulin Signaling in Human Adipocytes by Activation of the PP2A Phosphatase.New macrophage models of Gaucher disease offer new tools for drug development Applications of iPSC-derived models of Gaucher disease Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages.Lysosomal Disorders Drive Susceptibility to Tuberculosis by Compromising Macrophage Migration.A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism Disease models for the development of therapies for lysosomal storage diseases.Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Emerging therapeutic targets for Gaucher disease.The evolution of our understanding of macrophages and translation of findings toward the clinic.Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.New Directions in Gaucher Disease.Glycosylation and stem cells: Regulatory roles and application of iPSCs in the study of glycosylation-related disorders.Gaucher disease: Progress and ongoing challenges.The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.C9orf72: At the intersection of lysosome cell biology and neurodegenerative disease.Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned?The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease.Mechanisms of Gaucher disease pathogenesis The Spectrum of Neurological Manifestations Associated with Gaucher Disease.Impact of regulatory variation across human iPSCs and differentiated cells.Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.Human Induced Pluripotent Stem Cell-Derived Macrophages for Unraveling Human Macrophage Biology.Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.An hPSC-Derived Tissue-Resident Macrophage Model Reveals Differential Responses of Macrophages to ZIKV and DENV Infection

P2860

Q26825082-8DACE1E4-713D-4308-A387-AD520CA1551D Q33574148-5367953E-0BBD-4DE8-A049-42104CECB8FA Q33796396-F6A8782E-A5AC-4EDE-A0D8-2ABF03BF3056 Q33830512-F0CCD2E8-5228-47D5-B22D-8CF9CBE61B9B Q35024517-5C01D013-89D7-44E9-B211-DD47E90A18D7 Q35662057-2042E78C-93B7-455D-82E4-9CFEF37AD776 Q35747464-F2F21472-2530-4C99-B3B9-06DC22646227 Q36352522-8BBBD597-9DF0-4E74-B68E-4DB47DA78939 Q36475219-675F0CD4-BD6D-4DA6-8F9B-EBF3F191F375 Q36761911-B59C5974-614C-4FB2-8BA9-3CDBD85722A3 Q37096051-FC7357B7-0709-4B6E-A5ED-9EE4D1C82999 Q37110592-AE9EB978-0E5B-4ABB-A80B-93DF6FCA27B4 Q37548335-DEEE41B1-38DD-4B52-92C2-54914CD8AC84 Q37619231-60C01168-3059-4A53-9952-B2AC70553769 Q37738863-26DB4C71-81D1-4A05-A63D-3B812B9C2C80 Q38270518-6485A2AF-C280-4596-A774-0150816FDBFB Q38272795-CAED9665-D810-4B16-9CB2-21E6D74C462B Q38727638-3B699853-74FD-44FE-BF3B-5E134C732AFA Q38765856-439E0FF4-5843-4A74-BCFE-E004D0386BEB Q38905996-ACD35518-7DEB-41FC-B227-1D7BDAEB6D31 Q38964383-0A7DADC5-6E2F-4D61-9FFB-22DCD40F1D20 Q39028972-4512113B-7F35-4A8F-8AC8-8FEC242BE772 Q39148146-F0EFDFB1-35D9-46B1-9BEE-B6DDBBF1BB0A Q39165154-0C69C475-563E-4C29-98B3-6775322E94BA Q39254537-820D1B80-C40F-44C8-9E94-E61C6755FE0A Q39282050-AD69505C-6068-4977-B307-6F2927DDFDEA Q42059532-09D490C6-9AC0-4F39-B616-156CEFB9154F Q42136746-DE888E3E-CF9D-4C3A-9033-2B5E2AF41939 Q45990501-764C9656-49D1-4902-91F9-078C59308377 Q47611385-BC16BFC0-1EDF-4780-990F-50EB8907E8A6 Q49573470-0A275CE0-F80F-4BBF-80BD-1BFABA2B811C Q50014672-04A74B8B-D0BB-4EE9-B577-3BBEF0B3BD86 Q56340954-E380144E-2206-4A74-9000-3677EA0C4C5C

P2860

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

http://www.wikidata.org/entity/Q34165147

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@ast

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@en

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@nl

type

label

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@ast

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@en

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@nl

prefLabel

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@ast

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@en

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@nl

P1433

Q34165147-61F75CAD-65D0-47B7-8858-DF20D07D13C2

P1476

Q34165147-0E720756-1852-42B1-90A0-02A572F91B98

P2093

Q34165147-056FCFB8-23A4-46CC-84A9-7D2A35BD5A5F

Q34165147-0E20706E-A88C-4409-93DC-6C5A31EA297B

Q34165147-12382BEE-B9C3-4568-A8FA-8C42A33EBC08

Q34165147-2800116A-987C-4AF7-B579-1A3E0681C81F

Q34165147-3C753673-FD49-4A70-95EC-C6359A1574FA

Q34165147-64D1B116-FB46-4F3A-A2BD-D4320C33BDBF

Q34165147-B132C8C9-6F25-41D7-8532-0662E1F040A7

Q34165147-C6F3FAF8-22FA-4A78-9701-67140B4FC3FF

Q34165147-C7ABEC42-475E-4875-A333-C766060D5510

Q34165147-D27E86C1-5AFC-4310-81F4-0638077334CF

P2860

Q34165147-0943A812-6D7B-4261-B684-052BFDBA0E95

Q34165147-1459C48E-D510-490E-B157-139B89F86C52

Q34165147-2933BF0E-174D-41F8-824D-2B96EB3C33D2

Q34165147-378A3EE5-90BA-48CC-8768-04C8D421A76C

Q34165147-39F5F6EA-A2A9-4E11-9C3E-0BEBD18A46E7

Q34165147-45D4607B-2BC3-433E-80AA-79CACF25E0B8

Q34165147-466176E1-EE61-4B4B-A556-C804FAAB283E

Q34165147-4BDC9435-5CDA-4D0E-AE90-7F9E8379B9FF

Q34165147-748E100C-703E-43E4-B503-2CEE205933C8

Q34165147-79C46D15-0A9A-4E3D-BB71-022125739F63

P304

Q34165147-E97BB192-7043-479B-8E2D-273F1B296AFA

P31

Q34165147-C290A0B1-DC2D-4217-9BDD-6D3BCC90B8B4

P356

Q34165147-30C0E54C-452D-4886-9DDE-7465D40168D3

P407

Q34165147-397939D3-F18F-41CF-A765-30BC5EE2340A

P433

Q34165147-EB6B221F-4101-46C5-81DE-DA9CD65667D8

P478

Q34165147-DFECF370-9789-4BFC-BBBE-9BAA1041CBF5

P50

Q34165147-960315E0-A5F8-4605-AE68-DB587A5DE784

Q34165147-EED873F2-E8FE-4517-BAA9-B39A80352AA6

P577

Q34165147-54EAB90D-88F7-4D08-AB58-0A93F16BE1C7

P5875

Q34165147-84172B45-E141-471E-9BAA-00D2B1185E13

P698

Q34165147-FEABE32E-36B3-4054-868B-1C623F246CEF

P921

Q34165147-877F9F6C-868A-49F2-AF22-292267820283

P932

Q34165147-3D869E18-D92D-423F-A521-84E5407F1AA8

P356

SCITRANSLMED.3008659

P1433

Science Translational Medicine

P1476

Macrophage models of Gaucher d ...... hogenesis and candidate drugs.

@en

P2093

Amalia Dutra

http://www.w3.org/2001/XMLSchema#string

Barbara K Stubblefield

http://www.w3.org/2001/XMLSchema#string

Ehud Goldin

http://www.w3.org/2001/XMLSchema#string

Ellen Sidransky

http://www.w3.org/2001/XMLSchema#string

Elma Aflaki

http://www.w3.org/2001/XMLSchema#string

Emerson Maniwang

http://www.w3.org/2001/XMLSchema#string

Grisel Lopez

http://www.w3.org/2001/XMLSchema#string

Juan Marugan

http://www.w3.org/2001/XMLSchema#string

Nahid Tayebi

http://www.w3.org/2001/XMLSchema#string

Nima Moaven

http://www.w3.org/2001/XMLSchema#string

P2860

Multicolor Spectral Karyotyping of Human Chromosomes

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease

Activation and assembly of the NADPH oxidase: a structural perspective

High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase

Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease

P304

240ra73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3008659

http://www.w3.org/2001/XMLSchema#string

P407

P433

240

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263056883

http://www.w3.org/2001/XMLSchema#string

P698

24920659

http://www.w3.org/2001/XMLSchema#string

P921

P932

4161206

http://www.w3.org/2001/XMLSchema#string